NOTIFICATION OF BOARD MEETING

VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR TQB3909 TABLET "BCL-2 INHIBITOR"

VOLUNTARY ANNOUNCEMENT – TQB2102 “HER2 BISPECIFIC ADC” RECEIVES THIRD BREAKTHROUGH THERAPY DESIGNATION FROM THE CDE

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2026

VOLUNTARY ANNOUNCEMENT - 21 RESEARCH RESULTS TO BE PRESENTED AT THE 2026 CSCO ANNUAL MEETING (INCLUDING 5 ORAL PRESENTATIONS)

VOLUNTARY ANNOUNCEMENT - ESTABLISH STRATEGIC JOINT VENTURE WITH TEMPO SCAN TO EXPAND ACCESS TO INNOVATIVE MEDICINE IN INDONESIA

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL ON IM-101 INJECTION “PRES1 RECOMBINANT FUSION PROTEIN” APPROVED BY THE NMPA

VOLUNTARY ANNOUNCEMENT - TRD205 "AT2R ANTAGONIST" GRANTED THE CDE'S BREAKTHROUGH THERAPY DESIGNATION